Join the Celebrex group to help and get support from people like you.
Celebrex News
PIK3CA Could Guide Use of COX-2 Inhibitors in Treatment for Colon Cancer
THURSDAY, June 27, 2024 – PIK3CA mutational status may be beneficial for predicting response to addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant chemotherapy in...
FDA Medwatch Alert: Drug Safety Communication: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - Avoid Use of NSAIDs in Pregnancy at 20 Weeks or Later
ISSUE: FDA is warning that use of NSAIDs around 20 weeks or later in pregnancy may cause rare but serious kidney problems in an unborn baby. This can lead to low levels of amniotic fluid surrounding...
FDA Approves Consensi (amlodipine and celecoxib) for Treatment of Hypertension and Osteoarthritis Pain
TEL AVIV, Israel, May 31, 2018 (GLOBE NEWSWIRE) – Kitov Pharma Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, announced today that the U.S. Food and Drug Administration...
FDA Medwatch Alert: Non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Drug Safety Communication - FDA Strengthens Warning of Increased Chance of Heart Attack or Stroke
[Posted 07/09/2015] ISSUE: FDA is strengthening an existing label warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) increase the chance of a heart attack or stroke. Based on ...
FDA Medwatch Alert: Celebrex (celecoxib) - Apr 7, 2005
After concluding that the overall risk versus benefit profile is unfavorable, FDA has requested Pfizer, Inc. to voluntarily withdraw Bextra (valdecoxib) from the market. This request is based on: *...
FDA Medwatch Alert: Celebrex (celecoxib) - Jun 15, 2005
FDA has requested that sponsors of all non-steroidal anti-inflammatory drugs (NSAID) make labeling changes to their products. FDA recommended proposed labeling for both the prescription and...
FDA Medwatch Alert: Celebrex (celecoxib) - Dec 21, 2004
FDA notified healthcare professionals that, based on emerging information, including preliminary reports from one of several long term National Institutes of Health (NIH) prevention studies, the risk...
FDA Medwatch Alert: COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
After concluding that the overall risk versus benefit profile is unfavorable, FDA has requested Pfizer, Inc. to voluntarily withdraw Bextra (valdecoxib) from the market. This request is based on: *...
Further information
Related condition support groups
Ankylosing Spondylitis, Osteoarthritis, Juvenile Rheumatoid Arthritis, Pain, Period Pain, Dysmenorrhea, Rheumatoid Arthritis, Spondyloarthritis